EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80

Alan Kennedy iD, Maximillian A Robinson iD, Claudia Hinze iD, Erin Waters, Cayman Williams, Neil Halliday, Simon Dovedi, David M Sansom iD

The EMBO Journal · 01.03.2023 · 42 (5)

DOI: 10.15252/embj.2022111556 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The EMBO Journal, online erschienen am 02.02.2023. Verfasst von Alan Kennedy und 7 weiteren Autor:innen. Beteiligte Einrichtung: UCL Institute of Immunity and Transplantation, London, UK. Hauptthemen laut MEDLINE: Immune Checkpoint Proteins, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Versus Arthritis, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CTLA‐4 and PD‐1 are key immune checkpoint receptors that are targeted in the treatment of cancer. A recently identified physical interaction between the respective ligands, CD80 and PD‐L1, has been shown to block PD‐L1/PD‐1 binding and to prevent PD‐L1 inhibitory functions. Since CTLA‐4 is known to capture and degrade its ligands via transendocytosis, we investigated the interplay between CD80 transendocytosis and CD80/PD‐L1 interaction. We find that transendocytosis of CD80 results in a time‐dependent recovery of PD‐L1 availability that correlates with CD80 removal. Moreover, CD80 transendocytosis is highly specific in that only CD80 is internalised, while its heterodimeric PD‐L1 partner remains on the plasma membrane of the antigen‐presenting cell (APC). CTLA‐4 interactions with CD80 do not appear to be inhibited by PD‐L1, but efficient removal of CD80 requires an intact CTLA‐4 cytoplasmic domain, distinguishing this process from more general trogocytosis and simple CTLA‐4 binding to CD80/PD‐L1 complexes. These data are consistent with CTLA‐4 acting as modulator of PD‐L1:PD‐1 interactions via control of CD80.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint ProteinsProgrammed Cell Death 1 ReceptorCTLA-4 AntigenB7-H1 AntigenLigandsB7-1 AntigenCell Adhesion Molecules

Stichwörter der Autor:innen

CD80CTLA4PD-L1checkpoint blockadetransendocytosis

Substanzen

CTLA-4 AntigenImmune Checkpoint ProteinsProgrammed Cell Death 1 ReceptorB7-H1 AntigenLigandsB7-1 AntigenCell Adhesion Molecules

Autor:innen und Institutionen

  • UCL Institute of Immunity and Transplantation, London, UK.
  • Early Oncology R&D, AstraZeneca, UK.

ORCID-Profile: Alan Kennedy, Maximillian A Robinson, Claudia Hinze, David M Sansom

Förderung

  • Wellcome Trust
  • Versus Arthritis
  • Medical Research Council
  • AstraZeneca

Zitieren

APA

Kennedy, A., Robinson, M. A., Hinze, C., Waters, E., Williams, C., Halliday, N., Dovedi, S., & Sansom, D. M. (2023). The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80. The EMBO Journal, 42(5). https://doi.org/10.15252/embj.2022111556

Vancouver

Kennedy A, Robinson MA, Hinze C, Waters E, Williams C, Halliday N, et al. The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80. The EMBO Journal. 2023;42(5). doi:10.15252/embj.2022111556

BibTeX
@article{Kennedy2023,
  author = {Kennedy, Alan and Robinson, Maximillian A and Hinze, Claudia and Waters, Erin and Williams, Cayman and Halliday, Neil and Dovedi, Simon and Sansom, David M},
  title = {The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80},
  journal = {The EMBO Journal},
  year = {2023},
  volume = {42},
  number = {5},
  doi = {10.15252/embj.2022111556}
}
Kostenlos starten →